

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	June 27, 2018

DALIRESP® (roflumilast)

LENGTH OF AUTHORIZATION: UP TO ONE YEAR

REVIEW CRITERIA:

- Must be 18 years of age or older.
- Must have a diagnosis of chronic obstructive pulmonary disorder with chronic bronchitis.
- Trial and failure (further exacerbations) on triple therapy with a long acting beta agonist, long acting muscarinic antagonist, and an inhaled corticosteroid and FEV₁ <50% predicted.

DOSING:

Start with 250mcg by mouth once daily for 4 weeks, then 500mcg once daily thereafter.